Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q3 EPS by 5c, Boosts FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.17, $0.05 better than the analyst estimate of $0.12. Revenue for the quarter came in at $34.3 million versus the consensus estimate of $34.9 million.
Sciclone Pharmaceuticals, Inc. sees FY2014 EPS of $0.64-$0.68, versus prior guidance of $0.51-$0.57 and the consensus of $0.49. SciClone continues to project revenue of $130 million to $135 million.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Hunterbrook discloses Meta short position as alternative data signals Muse cooling
- TD Cowen on Pepsico (PEP): 'Ongoing Weakness in North America Drives Guidance Cut'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
